NCT06661915 - A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential ThrombocythemiaMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative Neoplasm, Not Otherwise SpecifiedPolycythemia VeraPrimary MyelofibrosisSecondary Myelofibrosis

Interventions

PROCEDURE

Biospecimen Collection

Undergo buccal swab and blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Iadademstat

Given PO

Trial Locations (6)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

46307

RECRUITING

UChicago Medicine Northwest Indiana, Crown Point

60451

RECRUITING

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

RECRUITING

University of Chicago Medicine-Orland Park, Orland Park

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH